Antidiabetic Drugs from Natural Resources

A special issue of Medicines (ISSN 2305-6320).

Deadline for manuscript submissions: closed (31 January 2019) | Viewed by 4902

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmaceutical Biology, Kiel University, 24118 Kiel, Germany
Interests: isolation and characterization of bioactive natural products; quality control of medicinal plants and herbal products

Special Issue Information

Dear Colleagues,

Diabetes mellitus and its complications are one of the major health challenges of our time. Currently, more than 400 million adults are affected, a number that is expected to increase to 600 million people within the next two decades. Type 2 diabetes mellitus, or non-insulin dependent diabetes mellitus, is the most common type and its initial stages are treated with oral antidiabetics. Though antihyperglycemic agents with different mechanisms of action are commercially available, their adverse events and hepato-renal toxicity are pronounced. Thus, the discovery of new and safer medicines is urgently warranted.

Natural drug products have always been an important source of bioactives and drugs derived from nature still account for half of today’s approved therapeutics. This Special Issue, “Antidiabetic Drugs from Natural Resources”, is dedicated to the discovery of new antidiabetic lead compounds from nature. Research articles and reviews dealing with novel antidiabetic activities of natural products and/or natural sources of antidiabetics are therefore very welcome. Additionally, the evaluation of extracts and herbal preparations used for the treatment of diabetes mellitus by modern analytical techniques will be considered.

Dr. Serhat Sezai Çiçek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes mellitus
  • natural products
  • α-glucosidase
  • PPARγ
  • DPP IV
  • 11β-HSD1
  • SGLT2
  • PTP1B

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 959 KiB  
Article
Hypoglicemic and Hypolipedimic Effects of Ganoderma lucidum in Streptozotocin-Induced Diabetic Rats
by Erna Elisabeth Bach, Edgar Matias Bach Hi, Ana Maria Cristina Martins, Paloma A. M. Nascimento and Nilsa Sumie Yamashita Wadt
Medicines 2018, 5(3), 78; https://doi.org/10.3390/medicines5030078 - 28 Jul 2018
Cited by 17 | Viewed by 4472
Abstract
Background:Ganoderma lucidum (Leyss. Ex. Fr) Karst is a basidiomycete mushroom that has been used for many years as a food supplement and medicine. In Brazil, National Health Surveillance Agency (ANVISA) classified Ganoderma lucidum as a nutraceutical product. The objective of the present [...] Read more.
Background:Ganoderma lucidum (Leyss. Ex. Fr) Karst is a basidiomycete mushroom that has been used for many years as a food supplement and medicine. In Brazil, National Health Surveillance Agency (ANVISA) classified Ganoderma lucidum as a nutraceutical product. The objective of the present work was to observe the effects of an extract from Ganoderma lucidum in rats treated with streptozotocin, and an agent that induces diabetes. Method: Male Wistar rats were obtained from the animal lodging facilities of both University Nove de Julho (UNINOVE) and Lusiada Universitary Center (UNILUS) with approval from the Ethics Committee for Animal Research. Animals were separated into groups: (1) C: Normoglycemic control water; (2) CE: Normoglycemic control group that received hydroethanolic extract (GWA); (3) DM1 + GWA: Diabetic group that received extract GWA; and (4) DM1: Diabetic group that received water. The treatment was evaluated over a 30-day period. Food and water were weighted, and blood plasma biochemical analysis performed. Results: G. lucidum extract contained beta-glucan, proteins and phenols. Biochemical analysis indicated a decrease of plasma glycemic and lipid levels in DM rats induced with streptozotocin and treated with GWA extract. Histopathological analysis from pancreas of GWA-treated DM animals showed preservation of up to 50% of pancreatic islet total area when compared to the DM control group. In plasma, Kyn was present in diabetic rats, while in treated diabetic rats more Trp was detected. Conclusion: Evaluation from G. lucidum extract in STZ-hyperglycemic rats indicated that the extract possesses hypoglycemic and hypolipidemic activities. Support: Proj. CNPq 474681/201. Full article
(This article belongs to the Special Issue Antidiabetic Drugs from Natural Resources)
Show Figures

Figure 1

Back to TopTop